TAMPA, Fla.--(BUSINESS WIRE)--Morphogenesis Inc. recently announced that one of its platform technologies, an investigational immunotherapy treatment for cancers, will be developed by Morphogenesis and Novartis Animal Health under an exclusive worldwide co-development and commercialization agreement entered into in November 2009. Through this agreement, Morphogenesis and Novartis will work closely together to advance the new platform technology to the companion animal market.
